Clinical Trials Arena on MSN12h
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants
Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
Business Wire24d
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with ...
Biogen receives exclusive rights to commercialize ... STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine.
Bioengineered Protein Drugs Market Size To Cross USD 672.7 Billion By 2034, Growing At A CAGR Of 6.2% - Report By Transparency Market Research, Inc.
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
pharmaphorum9d
Biogen taps Envisagenics' AI to speed up RNA splicing R&D
Biogen has made a further push into RNA-based ... which is used as a template for protein synthesis in cells – is transformed into a mature form. As its name suggests, splicing involves snipping ...
MarketWatch1mon
Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...
The Business Journals1mon
Biogen details pipeline culling as it looks for more deals like HI-Bio acquisition
Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.
pharmaphorum5d
Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia
After getting a green light from the European Commission, Biogen’s Skyclarys is the first ... that lead to low levels of frataxin, a protein necessary for the correct functioning of mitochondria ...
Yahoo Finance24d
Biogen buys rights to Stoke’s rare epilepsy drug
Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...
Nasdaq3d
Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
MorphoSys will earn a one-time milestone payment of $35 million from Biogen. Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on ...
Pharmabiz2d
Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
Morningstar4d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
MorphoSys will earn a one-time milestone payment of $35 million from Biogen. Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on ...